Biogen reports litifilimab data and Jefferies keeps Buy on Biogen stock

Published on 10/05/2026 at 15:53 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Revenue reached USD 2.74 billion in the second quarter of 2026. Biogen stock costs EUR 195.62 on October 5, 2026 after EUR 195.40.

NASDAQ-Handelsfloor mit grünem BIOTECH INDEX-Anzeigetafel und Händlern an Bildschirmen — Biogen Inc. Biotech-Aktie an der NASDAQ mit steigendem Kursindex im Handelsaal ISIN US09062X1037, Illustration mit AI erstellt.

Biogen Inc. (ISIN US09062X1037) was trading at EUR 195.62 at Lang & Schwarz on October 5, 2026 at 3:39 p.m. CEST, up 0.11 percent versus the prior close of EUR 195.40. The company reported 52-week litifilimab data on October 2, while Jefferies maintained a Buy rating and set a USD 255.00 price target on October 1.

Litifilimab reaches Week 52

As FinanzNachrichten reported on October 2, 2026, that 27.20 percent of participants receiving litifilimab from the start of the AMETHYST study achieved clear or almost clear skin at Week 52, versus 19.00 percent at Week 24.

The CLASI-70 measure showed a similar improvement. The share reaching at least a 70 percent reduction in disease activity rose to 28.80 percent at Week 52 from 21.70 percent at Week 24. Among participants who switched from placebo, 33.70 percent reported clear or almost clear skin at Week 52.

Revenue rises as profit falls

Biogen's second-quarter 2026 revenue reached USD 2.74 billion, up 3.40 percent from USD 2.65 billion a year earlier, according to Markets Insider. Net profit was USD 97.5 million, down 84.64 percent from USD 634.8 million in the comparable quarter.

The contrast matters for the stock narrative. Clinical progress broadens Biogen's pipeline case, but the latest quarterly figures show that revenue growth did not translate into higher net profit. Litifilimab remains investigational, and the AMETHYST Phase 3 readout is expected in the first half of 2027.

Analyst target stays above Nasdaq price

According to Markets Insider on October 1, 2026, Jefferies analyst Andrew Tsai maintained a Buy rating and set a USD 255.00 target. Bernstein had maintained a Buy rating with a USD 236.00 target in a report released on September 25, 2026.

Biogen's primary listing is Nasdaq under ticker BIIB. The next earnings report is listed for October 28, 2026 by Investing.com. That date gives the market a defined checkpoint for judging whether pipeline momentum is beginning to offset the earnings pressure visible in the second quarter.

Biogen stock holds near yearly high

At Lang & Schwarz, Biogen stock was trading at EUR 195.62 on October 5, 2026 at 3:39 p.m. CEST, plus 0.11 percent versus the prior close of EUR 195.40. The US-listed shares had a USD 32.4 billion market capitalization and a 52-week range of USD 138.00 to USD 230.49 as of October 5, 2026. The further course of trading is shown by the continuously updated real-time quote of Biogen stock.